Patents by Inventor Todd Lee Vanarsdale

Todd Lee Vanarsdale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY
    Publication number: 20230321042
    Abstract: This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.
    Type: Application
    Filed: July 16, 2021
    Publication date: October 12, 2023
    Applicant: PFIZER INC.
    Inventors: Stephen George DANN, Nichol Lee Goodman MILLER, Todd Lee VANARSDALE
  • CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS
    Publication number: 20230158034
    Abstract: The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.
    Type: Application
    Filed: April 7, 2021
    Publication date: May 25, 2023
    Applicants: Pfizer Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Mansi Arora, Stephen George Dann, Nichol Lee Goodman Miller, Sabrina Spencer, Todd Lee VanArsdale
  • P-cadherin antibodies
    Patent number: 8974781
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: March 10, 2015
    Assignee: Pfizer Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • P-CADHERIN ANTIBODIES
    Publication number: 20110182884
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: April 4, 2011
    Publication date: July 28, 2011
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • P-cadherin antibodies
    Patent number: 7928214
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 19, 2011
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • P-CADHERIN ANTIBODIES
    Publication number: 20090118487
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Inventors: CHRISTOPHER TODD BAUER, MAUREEN JERI BOURNER, MELANIE BOYLE, GERALD FRIES CASPERSON, DAVID WILLIAM GRIGGS, RICHARD DAVID HEAD, WILLIAM DEAN JOY, RICHARD ALLEN MAZZARELLA, RALPH RAYMOND MINTER, MARK ALLEN MOFFAT, BARRETT RICHARD THIELE, TODD LEE VANARSDALE
  • P-cadherin antibodies
    Patent number: 7452537
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: November 18, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale